Novartis response to COVID-19
In the face of a global crisis, Novartis has quickly mobilized R&D capabilities, medicines, clinical trials expertise and philanthropic aid to ...
NIBR Science of Therapeutics Symposium: Coronavirus Antivirals
Watch videos from our science event focused on finding therapeutic solutions to this ongoing health crisis.
Molecular Partners’ COVID-19 antiviral candidate, Ensovibep, maintains potent neutralization against emerging viral variants in vitro
May 06, 2021
Novartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche’s Actemra/RoActemra®
April 16, 2021
Molecular Partners and Novartis report positive initial results from Phase 1 study of COVID-19 antiviral therapy
March 09, 2021
Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate
March 04, 2021
Novartis CEO joins Sal Khan in the Khan Academy Homeroom
In this podcast, Novartis CEO Vas Narasimhan and Sal Khan discuss about modern day breakthroughs in the world of medicine and what we can expect for the future of health as we emerge from COVID-19.
Novartis CEO outlines how to improve pandemic preparedness, warns another one is bound to happen
Novartis CEO Vas Narasimhan discusses how to improve pandemic preparedness at the CNBC Evolve Global Summit.
Can partnerships help boost vaccine supply?
An interview with Dr Steffen Lang, Global Head of Novartis Technical Operations on how Novartis is involved in manufacturing COVID-19 vaccines.
Containing COVID-19 to serve patient needs
The coronavirus crisis has not only challenged the medical community to seek new treatments and vaccines. Keeping up with the production of ...
Patients and Caregivers
Novartis is working to ensure supply of our medicines, enhance virtual services, protect the integrity of clinical trials and support patient organizations during the coronavirus disease (COVID-19) pandemic.
Novartis is working closely with healthcare professionals during the coronavirus disease pandemic. We are embracing new ways of working and have rapidly scaled up multichannel engagement.
Investors and Shareholders
Novartis is regularly updating our Investor and Shareholder communities on the impact of coronavirus disease (COVID-19) and our response.
Novartis is supporting candidates during the coronavirus disease (COVID-19) outbreak. During this time interviews will continue as planned and, where appropriate, will be switched to virtual interviews using readily available technology.
Novartis is providing suppliers with recommended good practices guidance during the coronavirus disease (COVID-19) pandemic based on the most up-to-date World Health Organization (WHO) technical information.
COVID-19 country resources
Novartis provides country-specific information about coronavirus disease (COVID-19) in local languages.
Novartis COVID-19 Response Fund
Novartis COVID-19 Response Fund is providing urgently-needed support for healthcare workers and communities in over 50 projects around the world.
Research and collaborations
Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19.
COVID-19 Therapeutics Accelerator
Novartis has joined the accelerator, coordinated by the Bill & Melinda Gates Foundation, Wellcome and Mastercard.
COVID Impacts Cancer Emergency Initiative
Novartis is supporting Conquer Cancer, the ASCO Foundation to allow for better understanding of COVID-19 in cancer care.
Novartis joins the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative.
Innovative Medicines Initiative (IMI)
Novartis is part of a consortium engaging with the Innovative Medicines Initiative (IMI) on their COVID-19 directed efforts.
EFPIA call for therapeutic treatments R&D
Novartis is making available several compounds from our libraries that are considered suitable for in vitro antiviral testing.
US Centers for Disease Control and Prevention (CDC)
CDC coronavirus disease (COVID-19) resources
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
COVID-19 online hub